Hypoxic Pulmonary Hypertension: Molecular Mechanisms and Clinical Research Advances

TL;DR

This review discusses the molecular causes and recent clinical progress in hypoxic pulmonary hypertension, a lung disease linked to chronic low oxygen.

Contribution

The paper integrates recent molecular mechanisms with clinical advances to propose precision medicine approaches for hypoxic pulmonary hypertension.

Findings

HPH involves HIF signaling, ion channel dysregulation, and metabolic changes.

Novel therapies include immunomodulation and epigenetic interventions.

Biomarkers like lactylation-associated proteins aid in risk stratification.

Abstract

Hypoxic pulmonary hypertension (HPH), classified as Group 3 pulmonary hypertension in the current clinical classification system, represents a complex and progressive cardiopulmonary disorder characterized by elevated pulmonary arterial pressure due to chronic alveolar hypoxia. This condition significantly contributes to morbidity and mortality in patients with chronic lung diseases and individuals residing at high altitudes. The pathogenesis of HPH involves a multifactorial interplay between sustained hypoxic pulmonary vasoconstriction, pulmonary vascular remodeling, endothelial dysfunction, and inflammatory responses. This review provides a comprehensive synthesis of recent advances in HPH pathophysiology and their clinical translation, with a focus on integrating molecular mechanisms with emerging therapeutic strategies. The pathogenesis of HPH involves a complex interplay of hypoxia-inducible factor (HIF) signaling, mechanosensitive ion channel dysregulation (particularly TRPC channels), metabolic reprogramming featuring glycolytic shift and mitochondrial dysfunction, immune–inflammatory mechanisms including macrophage-centered immunopathology, and dysregulation of the nitroxidergic system. Recent clinical advances include refined risk stratification using advanced echocardiographic techniques, identification of novel biomarkers such as lactylation-associated proteins, and development of targeted therapies including immunomodulatory approaches, metabolic modulators, and epigenetic interventions. Ongoing clinical trials are investigating innovative strategies ranging from iron supplementation to nanoparticle-based drug delivery systems. Despite these advances, significant translational challenges remain, including limitations of preclinical models, patient heterogeneity, and the need for HPH-specific outcome measures. This review bridges the gap between mechanistic insights and clinical applications, offering an integrated framework that highlights precision medicine approaches, emerging therapeutic targets, and priority research directions for improving outcomes in this challenging condition.

Figures